Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

NCT04047017 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Gestational Trophoblastic Disease

Interventions

DRUG: Apatinib
DRUG: Camrelizumab

Sponsor

Peking Union Medical College Hospital